Bolt Biotherapeutics, Inc.
BOLTNext catalyst
BDC-4182
Gastric Cancer Adenocarcinoma Metastatic
Get an email about BOLT's next catalysts
Track Bolt Biotherapeutics (BOLT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
BOLT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-2.40 | FQ end Sep/2026 | Call: tbd
BDC-4182 Phase 2 Est. Readout
Primary completion for BDC-4182 trial (NCT06921837) in Gastric Cancer Adenocarcinoma Metastatic
SourceHow BOLT's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BDC-4182 | Phase 2 | Gastric Cancer Adenocarcinoma Metastatic | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Bolt Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Bolt Biotherapeutics, Inc.'s (BOLT) pipeline across Phase 2. Its lead program is BDC-4182 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bolt Biotherapeutics, Inc.'s next FDA catalyst?→
Bolt Biotherapeutics, Inc.'s (BOLT) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BOLT biotech catalysts?→
Add BOLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bolt Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.